Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Engineering
  7. Biomedical Engineering
  9. Medical Devices
  11. Targeted Delivery Of Doxorubicin Toward 4 T1 Cells Via In Situ Binding Between Maleimide Functionalized As1411 - Nh2 Aptamer And Endogenous Albumin

Targeted delivery of doxorubicin toward 4 T1 cells via in situ binding between maleimide functionalized AS1411 - NH2 aptamer and endogenous albumin

Yasamin Hamooni1, Ali Samie1, Mona Alibolandi2

  • 1Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran.

International Journal of Biological Macromolecules
|June 14, 2025

Related Experiment Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

5.9K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K

View abstract on PubMed

Summary
This summary is machine-generated.

This study introduces a novel Trojan horse drug delivery system using an aptamer-PEG-albumin conjugate for targeted doxorubicin delivery. This system effectively shrinks or eliminates tumors with reduced toxicity in mice.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Targeted drug delivery aims to enhance therapeutic efficacy and minimize side effects.
  • Albumin, a common blood protein, can be utilized for targeted delivery due to its natural circulation.
  • Developing efficient drug carriers is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To develop and characterize a novel Trojan horse drug delivery system for targeted delivery of doxorubicin (DOX).
  • To evaluate the in vitro and in vivo efficacy and safety of the DOX-loaded aptamer-PEG-albumin complex.
  • To investigate the potential of this system for cancer therapy by assessing tumor targeting and toxicity.

Main Methods:

  • Synthesis and characterization of AS1411 aptamer-PEG-albumin conjugate.
Keywords:
Endogenous albuminIn situ SA − hitchhikingTrojan horse strategy

Related Experiment Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

5.9K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K
  • Doxorubicin loading and release studies.
  • In vitro cell-based assays (MTT, live/dead, flow cytometry, apoptosis/necrosis, fluorescence imaging).
  • In vivo studies in 4T1 tumor-bearing mice, including efficacy, biodistribution, and toxicity assessments.

    • Main Results:

    • Successful formation and characterization of the DOX-Apt-PEG-HSA/MSA complex.
    • Demonstrated pH-sensitive drug release and good stability.
    • Validated in vitro cellular uptake, cytotoxicity, and apoptosis induction.
    • Achieved significant tumor shrinkage or ablation in 4T1 tumor-bearing mice with reduced off-target organ accumulation and toxicity.

    Conclusions:

    • The developed Trojan horse system shows promise as an effective and safe targeted drug delivery platform for cancer therapy.
    • Albumin-mediated targeting significantly enhances drug accumulation at the tumor site.
    • This strategy offers a potential approach to improve the therapeutic index of chemotherapeutic agents like doxorubicin.